January 2026 Research Update

This month, the clearest treatment signal came from real-world comparisons suggesting that adding daratumumab (a CD38 antibody) to first treatment may lead to faster and deeper control of the abnormal light chains, with earlier organ improvements in some patients. At the same time, short follow-up meant survival differences were not clearly shown, reminding readers that early response and long-term outcomes are not always the same thing. A broader review of cardiac imaging studies also aligned with the idea that when the underlying disease is brought under control, heart structure and function measurements often look more stable or improved over time. [1] [2]

In a matched retrospective comparison of newly diagnosed AL amyloidosis, a frequency-adjusted, cyclophosphamide-free daratumumab-based regimen reached complete blood response more often at 6 and 12 months, and did so sooner than bortezomib plus dexamethasone. Cardiac and kidney organ responses were also reported more often at 6 months with the daratumumab-based approach, while the safety profile looked similar in this dataset and no clear short-term survival advantage was seen. Because this was not a randomized trial and numbers were modest, it best fits as supportive evidence rather than a final answer. [1]

Across studies of cardiac amyloidosis summarized in a systematic review, imaging measurements of heart function (like strain) and heart wall thickness tended to improve or be preserved when disease-modifying therapy worked in ATTR, and when a complete blood response was achieved in AL. Changes in one MRI-based measure of amyloid burden (extracellular volume) were inconsistent, which matters because it suggests some imaging markers may track recovery differently than others. For patients, the main message is that researchers are increasingly using imaging as a way to measure whether the heart is improving, but not all imaging changes move together. [2]

For patients and caregivers, this theme adds to the picture that deeper, faster control of the light-chain problem often goes along with earlier organ improvement, at least in some real-world reports. The daratumumab-based comparison is still observational, so it cannot prove one approach is better for everyone, and it did not show a clear short-term survival difference in the reported timeframe. The imaging review mainly matters as research context: it supports the idea that heart imaging can reflect response, but it also shows that some scans may not change in a simple or consistent way even when treatment is working. [1] [2]

Several studies this month focused on how to estimate risk and track organ involvement, especially in the heart and liver, using practical measurements. The common pattern was that simple, repeatable markers can help sort people into higher- and lower-risk groups, and that organ response over time (not just blood response) carries important survival information. Together, these studies aim to make monitoring more consistent and more closely tied to outcomes that matter to patients. [3] [4] [5]

For the liver, two multicenter analyses supported alkaline phosphatase (a routine blood test linked to bile flow) as a meaningful way to judge hepatic response in AL amyloidosis with liver involvement. One study defined liver response as a greater than 50% drop (or normalization) in alkaline phosphatase and reported that achieving this response, especially by 12 months or at best response, was linked to better survival. Another study suggested that a simpler two-level liver response system predicted survival better than a more complex four-level system, and that an early complete blood response increased the chance of later liver response. [4] [5]

For the heart rhythm, a retrospective study in cardiac amyloidosis (including AL and ATTR) developed the Amy-Lyon AF score to estimate the chance of developing atrial fibrillation after diagnosis in people who did not have it at baseline. The score combined clinical and ECG features, and higher scores were linked to a much higher 2-year rate of new atrial fibrillation in this dataset. This work is best viewed as an early tool that needs further testing, but it reflects a push toward earlier identification of rhythm risk. [3]

For kidney involvement in the setting of plasma cell disease, a biopsy-based analysis in people with multiple myeloma compared different kidney injury patterns, including AL amyloidosis. AL cases stood out for nephrotic-range protein loss in the urine, and ongoing need for dialysis was the strongest marker of worse survival, more so than the degree of kidney function improvement. While this study was not limited to AL amyloidosis, it reinforces that the type of kidney injury and whether dialysis continues are major parts of the prognosis story in light-chain related disease. [6]

This theme matters now because it tightens how researchers connect test results to outcomes people care about, like survival and complications. The liver studies suggest that changes in a single common blood test over months can capture meaningful liver improvement and can be used consistently in research and follow-up, although the best timing and definitions are still being refined. The atrial fibrillation score is earlier-stage evidence and does not by itself determine what should happen for an individual, but it helps clarify that rhythm problems are predictable enough to study with structured tools. The kidney biopsy study mainly adds understanding: it highlights that different kidney patterns behave differently, and that remaining on dialysis was a key signal of risk in that cohort. [4] [5] [3] [6]

This month added several pieces that point in the same direction: diagnosing AL amyloidosis correctly often requires combining blood and urine testing with tissue proof, and heart imaging can support the workup but can also mislead if used alone. Larger studies strengthened the performance of certain imaging approaches and ECG-based calculations, while case reports showed real-world situations where one amyloid type can mimic another or where another illness can look like amyloidosis. The overall picture is progress toward more accurate, less invasive diagnosis, alongside reminders to confirm the amyloid type carefully. [7] [8] [9] [10] [11]

New ASH guidelines described a structured diagnostic approach for suspected AL amyloidosis, emphasizing blood and urine tests that look for a monoclonal light-chain problem and recommending tissue confirmation. They stated that diagnosis can often be made through surrogate biopsies that include both bone marrow and a fat pad sample, while noting that a target-organ biopsy may be preferred in some situations. For patients, this is a clarity update on what a complete diagnostic evaluation often includes, rather than a report of new trial results. [7]

For heart involvement, a meta-analysis reported that cardiac MRI with late gadolinium enhancement had high sensitivity and specificity for detecting cardiac involvement in biopsy-proven AL amyloidosis, while echocardiography measures had more variable accuracy. The authors rated the overall certainty as very low, which means the numbers should be read as suggestive rather than definitive. Still, the pattern supports why MRI is often studied as a strong tool when the question is whether amyloid is affecting the heart. [8]

An ECG-based study reported that combining voltage readings from the ECG with heart size measurements (from echocardiography) helped distinguish AL cardiac amyloidosis from other causes of thickened heart muscle, such as hypertrophic cardiomyopathy or high blood pressure-related thickening. One voltage-mass ratio (VMR2) had the best accuracy in that single-center Chinese dataset, with cutoffs aimed at either ruling in or ruling out AL cardiac amyloidosis. This approach is attractive because it uses widely available tests, but the study noted a need for validation in other populations. [9]

Early imaging research also evaluated a PET tracer called [18F]Florbetazine, showing strong binding to AL and ATTR amyloid in lab testing and clear heart and kidney uptake in 1 person with AL amyloidosis, with low background signal in 2 healthy volunteers. This is not yet a proven clinical test, but it shows active work toward PET scans that directly highlight amyloid deposits. For patients, it is best seen as a potential future diagnostic option that requires larger studies. [12]

Case reports illustrated why confirming amyloid type and considering look-alike conditions matters. One person had strongly positive bone-avid scintigraphy that looked like ATTR, but blood testing and biopsies confirmed AL amyloidosis, showing that AL can sometimes mimic ATTR on this scan. Another report described a patient after stem cell transplant whose thickened heart and shock were explained by viral myocarditis on cardiac MRI rather than AL amyloidosis, underlining how imaging can also help avoid a wrong diagnosis. [10] [11]

For patients, this theme mainly affects understanding of diagnosis rather than introducing a new treatment. The guidelines and research together reinforce that correctly typing amyloid (confirming AL versus other forms) depends on combining protein tests with tissue confirmation, because some scans can look similar across amyloid types. The MRI and ECG studies may matter now as supportive evidence for tools already used in many centers, but the certainty and generalizability are still evolving, especially across different populations and healthcare settings. The PET tracer work is early-stage and mainly matters for the future if larger studies confirm it can reliably find amyloid and help track it over time. [7] [8] [9] [12] [10] [11]

This month’s case reports and small case series broadened the real-world picture of how AL amyloidosis can appear and evolve, including uncommon starting symptoms, localized forms, and complex overlap with other diseases. The shared pattern was variability: some patients improved with anti-plasma cell therapy or local surgery, while others had severe heart involvement or later rhythm problems despite good blood responses. These reports do not tell how common any pattern is, but they help patients recognize that AL amyloidosis can be diverse and sometimes confusing to diagnose. [13] [14] [15] [16] [17] [18] [19] [20] [21]

Several reports highlighted non-typical first clues to systemic AL amyloidosis. One patient presented with prominent skin changes and an enlarged tongue and improved after bortezomib plus dexamethasone, with stable heart and kidney function on follow-up. Another presented with interstitial lung disease and pleural fluid and was initially misdiagnosed before monoclonal protein testing and biopsy confirmed AL amyloidosis. [13] [17]

Other cases emphasized complexity in cardiac AL amyloidosis beyond the initial response to therapy. One patient had deep blood remission after daratumumab-based therapy and stem cell transplant, yet later had a long pause in heart rhythm captured by an implantable monitor and then received a pacemaker, with symptom improvement afterward. Another patient with advanced cardiac AL amyloidosis and underlying multiple myeloma was treated with a bortezomib-cyclophosphamide-based regimen but died within months of diagnosis, reflecting the poor outcomes that can occur with late-stage cardiac involvement. [15] [14]

A few reports focused on rarer contexts and overlaps. One case described AL amyloidosis diagnosed after recovery from COVID-19, with remission of bone marrow plasma cells after CyBorD, while the authors noted that a causal link cannot be proven from a single case. Another described dual cardiac infiltration by AL and ATTR confirmed on heart biopsy, showing that more than one amyloid type can be present in the same person. A separate case linked multisystem AL amyloidosis with an SGPL1 gene mutation and reported stabilization with immunomodulatory therapy, but mechanistic explanations remained hypothetical. [16] [19] [20]

Localized amyloid reports and a small pulmonary series focused on follow-up questions rather than systemic therapy. A surgical case of localized cutaneous nodular amyloidosis (AL-type kappa) reported no recurrence at 21 months with no evidence of systemic disease. In a three-person series of nodular pulmonary amyloidosis, each person later had a lymphoproliferative disorder identified over time, raising the possibility that this lung finding can coexist with or precede certain blood or lymph system conditions. [18] [21]

For patients and caregivers, these reports mainly add context and awareness rather than changing what is known with high certainty. They help clarify that AL amyloidosis can start with skin, lung, liver, kidney, or heart problems, and that confirming the diagnosis often depends on finding a monoclonal light-chain problem and proving amyloid in tissue. They also show that recovery can look different across body systems, including situations where heart rhythm issues appear even after strong blood responses. Because these are individual cases, it remains uncertain how often any of these patterns occur, but they can help people understand why AL amyloidosis is often evaluated and followed in a multi-organ way. [13] [17] [15] [14] [16] [19] [20] [18] [21]

Biology studies this month reinforced a simple idea: AL amyloidosis is not one uniform material, and the exact light-chain gene and protein shape can differ across people and organs. Large patient data linked specific light-chain gene families to different patterns of kidney and other organ involvement. Lab and tissue-structure studies showed that light-chain proteins can form patient-specific fibril shapes and that small molecules can sometimes stabilize these proteins in ways that might reduce their tendency to break down. [22] [23] [24]

In a cohort of Chinese patients with renal AL amyloidosis, researchers identified the light-chain variable gene in most cases and reported that different gene families lined up with different clinical patterns. For example, one gene family was linked to a higher rate of full nephrotic syndrome, another was linked to heavier amyloid burden and more liver involvement, and a third was described as potentially predicting faster kidney progression and dialysis risk. This kind of work aims to explain why two people with AL amyloidosis can have different organ problems and different disease speeds. [22]

A structural study that extracted amyloid from fat and heart biopsies of 3 people found five distinct fibril structures and showed that fibril shapes were different from person to person. Within a given person, fibrils from different tissues were broadly similar, with smaller local differences that may reflect the tissue environment. For patients, this supports the idea that both the individual light-chain sequence and the organ environment may shape the disease. [23]

In laboratory experiments on multiple AL-associated light chains, several small molecules bound the proteins and reduced signs of unfolding and breakdown, with one compound (M83) showing strong effects at lower concentrations in these assays. The researchers also observed that binding tended to promote light-chain dimer formation, which may help keep the protein in a more stable shape. This is early-stage research and does not show patient benefit, but it points to one possible future strategy aimed at stabilizing light chains directly, not only suppressing their production. [24]

This theme is mainly about future understanding and future therapies rather than immediate changes in care. The gene and structure studies help explain why AL amyloidosis can look so different across patients, which may eventually support more personalized prediction of organ risk. The small-molecule stabilization work is still lab-based and it remains uncertain whether these compounds can be made into safe, effective treatments in people. Even so, this month makes it clearer that researchers are tackling AL amyloidosis not only at the level of plasma cells, but also at the level of the light-chain protein and the amyloid material itself. [22] [23] [24]